Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
92.97 USD +1.38% Intraday chart for BioNTech SE +3.30% -11.91%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating MT
News Highlights : Top Company News of the Day - Tuesday at 7 AM ET DJ
European Midday Briefing : Investors Hold Back Ahead of Key Inflation Print DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
BioNTech gets US agency notice over default on COVID vaccine royalties RE
Moderna, Inc. prepares for the post-Covid era Our Logo
BioNTech gets notice from US agency over default on COVID vaccine royalties RE
BioNTech gets notice from NIH on default on royalties RE
BIONTECH : Deutsche Bank remains Neutral ZD
TD Cowen Adjusts BioNTech Price Target to $95 From $101, Maintains Market Perform Rating MT
BIONTECH : A miss is a miss Alphavalue
BIONTECH : Deutsche Bank reaffirms its Neutral rating ZD
BIONTECH : Goldman Sachs reiterates its Neutral rating ZD
Wall St ends higher as Fed sees three rate cuts RE
BIONTECH : Jefferies sticks Neutral ZD
Sector Update: Health Care Stocks Ease Late Afternoon MT
Sector Update: Health Care Stocks Down Wednesday Afternoon MT
Sector Update: Health Care MT
BioNTech's Fourth-Quarter Results Miss Views; Guides 2024 Revenue Decline MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
Stocks in motion: Chipotle surges after stock split, Mobileye's new partnership boosts shares Our Logo
BIONTECH : UBS gives a Neutral rating ZD
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Sector Update: Health Care MT
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
85.92 EUR
Average target price
109.1 EUR
Spread / Average Target
+26.95%
Consensus
  1. Stock
  2. Equities
  3. Stock BioNTech SE - Nasdaq
  4. News BioNTech SE
  5. BioNTech : Completes Acquisition of Gilead Subsidiary's Neoantigen TCR Cell Therapy R&D Platform -- BioNTech Shares Surge